Stock Taper
SCREENER COMPARE ANY 2 STOCKS
JSPR
JASPER THERAPEUTICS, INC.
NASDAQ
$0.70
▲ UP 0.07% (0.00)

KEY STATISTICS

Market Cap$11.37 M
52w High$2.87
52w Low$0.32
Dividend Yield—
Frequency—
P/E-0.22
Volume265.03K
Shares Out.16.25M

COMPANY

LEADERSHIP

Jeetinder Singh Mahal
CHIEF EXECUTIVE
Jeetinder Singh Mahal

COMPENSATION 2026

Salary$110,417
Stock Awards$341,806
Incentive Plan Pay$0
All Other Comp.$242,111
Total$1,037,600

ABOUT

SECTOR
Healthcare
WENT PUBLIC
January 10, 2020
METHOD OF GOING PUBLIC
IPO
FULL TIME EMPLOYEES
22

PRICE TARGET

Target High$3.00
Target Low$2.00
Target Median$2.50
Target Consensus$2.50

UPCOMING EARNINGS

DateNov 9, 2026
DayMonday
Rev. Est.$12.00M
NOV
9
MON

SPLIT RECORD

DATETYPERATIO
2024-01-04Reverse1:10

PRICE

$0.70 ▲ UP 0.07% (+$0.00)
OVERLAYS
$0.67$0.69$0.709:32 AM10:37 AM11:41 AM12:45 PM1:50 PM2:55 PM3:59 PM0.70

About Jasper Therapeutics, Inc.

https://jaspertx.com ↗

Jasper Therapeutics, a Redwood City biotech, develops conditioning agents and engineered stem cell therapies, with lead candidate JSP191, to improve hematopoietic stem cell transplantation and gene therapy outcomes.

INDUSTRY

Biotechnology

A PRODUCT JASPER THERAPEUTICS, INC. IS KNOWN FOR

Briquilimab
Briquilimab

Briquilimab is Jasper Therapeutics' clinical-stage antibody targeting c-Kit (CD117), currently in trials for mast cell-driven diseases like CSU and asthma.

COMPETITORS

COMPETITOR
CLDX COMPARE
COGT COMPARE
NVS COMPARE
REGN COMPARE

ETFS HOLDING THIS STOCK

ETFS HOLDING
11
LISTED HERE
1
RANKED BY POSITION SIZE
VTS.AX
0.00% · 833.4K

INSTITUTIONAL OWNERSHIP

SHARES OWNED
100.00%
HOLDERS
86
TOP 12 OF 86 · RANKED BY POSITION SIZE
Abingworth Llp
5.6M sh · $2.72M
Velan Capital Investment Management LP
2.7M sh · $2.34M
Morgan Stanley
2.0M sh · $3.6M
Acorn Capital Advisors, LLC
1.8M sh · $3.27M
Goldman Sachs Group Inc
1.7M sh · $3.2M
Millennium Management LLC
1.6M sh · $1.42M
Soleus Capital Management, L.P.
1.5M sh · $3.56M
Kingdon Capital Management, L.L.C.
1.4M sh · $1.18M
Vanguard Group Inc
1.3M sh · $2.43M
Rock Springs Capital Management LP
1.1M sh · $2.01M
Carlyle Group Inc.
1.1M sh · $934.2K
Woodline Partners LP
1.0M sh · $1.9M

RATINGS SNAPSHOT

Overall rating: C+

DCFROEROAD/EP/EP/B
Discounted Cash Flow5
Return On Equity1
Return On Assets1
Debt To Equity3
Price To Earnings1
Price To Book1
Overall Score2

INSIDER TRADES

★
DIRECTOR
Shizuru Judith Anne
Purchase · 7.5K shares
2026-07-31
★
DIRECTOR
WIGGANS THOMAS G
Purchase · 7.5K shares
2026-07-31
★
DIRECTOR
Lucas Svetlana
Purchase · 7.5K shares
2026-07-31
★
DIRECTOR
Crutcher Patrick J
Purchase · 7.5K shares
2026-07-31

MOST RECENT ANALYST GRADES

GRADE SUMMARY
SECTOR PERFORM 1
HOLD 1
OUTPERFORM 1
BUY 1
MARKET OUTPERFORM 1
5 GRADES IN THE LAST 12 MONTHS
RBC Capital SECTOR PERFORM TD Cowen HOLD Evercore ISI Group OUTPERFORM BTIG BUY JMP Securities MARKET OUTPERFORM

SECTORS PEERS

PEERPRICE
QTTB$15.03COMPARE
SABS$3.79COMPARE
VRCA$5.69COMPARE
BOLD$2.83COMPARE
CELU$1.58COMPARE
NXTC$6.09COMPARE
BTAI$0.18COMPARE